<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20080">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01992211</url>
  </required_header>
  <id_info>
    <org_study_id>BCWP1202_102</org_study_id>
    <nct_id>NCT01992211</nct_id>
  </id_info>
  <brief_title>Evaluating of Pharmacokinetic Profile of BCWP_C001 and Co-administration of Rosuvastatin and Metformin</brief_title>
  <official_title>Clinical Trials to Evaluate the Pharmacokinetic Profiles and Safety/Tolerability of BCWP_C001 Formulation Compared to Coadministration of Rosuvastatin and Metformin SR Formulation, and to Evaluate the Effect of Food on the Pharmacokinetic Profile of BCWP_C001 After Single Oral Administration to Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BC World Pharm Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BC World Pharm Co. Ltd.</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetic Profile and Safety/Tolerability
      of BCWP_C001 compared to Co-Administration of Crestor 10mg and Glucophage XR 500mg, and to
      evaluate the food effect of Pharmacokinetic profile of BCWP_C001 after administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical Trials to Evaluate the Pharmacokinetic Profiles and Safety/Tolerability of
      BCWP_C001 Formulation compared to Coadministration of Rosuvastatin and Metformin SR
      Formulation, and to Evaluate the Effect of Food on the Pharmacokinetic Profile of BCWP_C001
      after Single Oral Administration to Healthy Male Subjects.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rosuvastatin, Metformin Cmax, AUClast</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>N-desmethyl rosuvastatin Cmax</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-desmethyl rosuvastatin AUClast</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-desmethyl rosuvastatin AUCinf</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rosuvastatin, N-desmethyl rosuvastatin, Metformin AUCinf</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rosuvastatin, N-desmethyl rosuvastatin, Metformin Tmax</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rosuvastatin, N-desmethyl rosuvastatin, Metformin t1/2</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rosuvastatin, N-desmethyl rosuvastatin, Metformin Vz/F</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rosuvastatin, N-desmethyl rosuvastatin, Metformin CL/F</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin and Metformin SR, C001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Sequence 1(ABC)
Rosuvastatin 10mg and Metformin SR 500mg(Fed) ---&gt; wash out ---&gt; BCWP_C001(Fasted) ---&gt; wash out ---&gt; BCWP_C001(Fed)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 2(ACB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastain 10mg and Metformin SR 500mg(Fed) ---&gt; wash out ---&gt; BCWP_C001(Fed) ---&gt; wash out ---&gt; BCWP_C001Fasted)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 3(BAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCWP_C001(Fasted) ---&gt; wash out ---&gt; Rosuvastain 10mg and Metformin SR 500mg(Fed) ---&gt; wash out ---&gt; BCWP_C001(fed)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 4(BCA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCWP_C001(Fasted) ---&gt; wash out ---&gt; BCWP_C001(Fed) ---&gt; wash out ---&gt; Rosuvastain 10mg and Metformin SR 500mg(Fed)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 5(CAB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCWP_C001(Fed) ---&gt; wash out ---&gt; Rosuvastain 10mg and Metformin SR 500mg(Fed) ---&gt; wash out ---&gt; BCWP_C001(Fasted)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 6(CBA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCWP_C001(Fed) ---&gt; wash out ---&gt; BCWP_C001(Fasted) ---&gt; wash out ---&gt; Rosuvastain 10mg and Metformin SR 500mg(Fed)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin and Metformin SR(Fed)</intervention_name>
    <description>Co-administration of Rosuvastatin and Metformin SR</description>
    <arm_group_label>Rosuvastatin and Metformin SR, C001</arm_group_label>
    <arm_group_label>Treatment Sequence 2(ACB)</arm_group_label>
    <arm_group_label>Treatment Sequence 3(BAC)</arm_group_label>
    <arm_group_label>Treatment Sequence 4(BCA)</arm_group_label>
    <arm_group_label>Treatment Sequence 5(CAB)</arm_group_label>
    <arm_group_label>Treatment Sequence 6(CBA)</arm_group_label>
    <other_name>Crestor 10mg</other_name>
    <other_name>Glucophage XR 500mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCWP_C001(Fasted)</intervention_name>
    <description>Combination of Rosuvastatin 10mg+Metformin SR 500mg (Fasted)</description>
    <arm_group_label>Rosuvastatin and Metformin SR, C001</arm_group_label>
    <arm_group_label>Treatment Sequence 2(ACB)</arm_group_label>
    <arm_group_label>Treatment Sequence 3(BAC)</arm_group_label>
    <arm_group_label>Treatment Sequence 4(BCA)</arm_group_label>
    <arm_group_label>Treatment Sequence 5(CAB)</arm_group_label>
    <arm_group_label>Treatment Sequence 6(CBA)</arm_group_label>
    <other_name>BCWP_C001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCWP_C001(Fed)</intervention_name>
    <description>Combination of Rosuvastatin 10mg+Metformin SR 500mg (Fed)</description>
    <arm_group_label>Rosuvastatin and Metformin SR, C001</arm_group_label>
    <arm_group_label>Treatment Sequence 2(ACB)</arm_group_label>
    <arm_group_label>Treatment Sequence 3(BAC)</arm_group_label>
    <arm_group_label>Treatment Sequence 4(BCA)</arm_group_label>
    <arm_group_label>Treatment Sequence 5(CAB)</arm_group_label>
    <arm_group_label>Treatment Sequence 6(CBA)</arm_group_label>
    <other_name>BCWP_C001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Male Volunteer, age 20 to 45 years at the time of screening

          -  Body weight is not less than 55kg, not more than 90kg and the result of Body Mass
             Index(BMI) is not less than 18.5, not more than 25.0

          -  Subject who has no congenital, chronic disease, and no disease symptom or finding in
             medical examination result

          -  Subject who is judged to be eligible by principal investigator or sub-investigator
             according to various test results(clinical laboratory test, 12-lead ECG etc)

          -  Subject who comprehended the purpose, contents of the study, property of clinical
             drug and signed the informed consent to participate in the trial having the
             willingness

        Exclusion Criteria:

          -  Subject who has history of hypersensitivity reaction for relevant drug(statin,
             biguanide) or clinically significant hypersensitivity reaction

          -  Subject who has history or presence of clinically disease in liver, kidney,
             gastrointestinal tract, respiratory system, musculoskeletal, endocrine system, mental
             disorder, blood-tumor, cardiovascular. Particulary, subject who has bleeding disorder
             or tend to be bleeding with bruised easily

          -  Subject who has family history of hereditary muscular disorder or muscular side
             effect

          -  Subject who has history of gastrointestinal tract disorder which can affect the drug
             absorption or surgery(excluding appendectomy, hernia surgery)

          -  Subject who had taken diagnosis with peptic ulcer within 2 month prior to the drug
             administration

          -  Subject who has results of clinical laboratory test as follows :

        ㆍAST, ALT level exceed the normal range more than 1.5 times

        ㆍTotal bilirubin level exceed the normal range more than 1.5 times

          -  In the vital sign, systolic blood pressure is more than 150mmHg, less than 90mmHg or
             diastolic blood pressure is more than 90mmHg, less than 60mmHg

          -  Subject who has presence or history of drug abuse, or positive screening for drug
             abuse

             → Alcohol abuse defines to drink over 21 unit/week(alcohol 1unit = 10g = 12.5 mL)
             persistingly

          -  Subject who participated in another clinical trial within 3 month prior to the drug
             administration

          -  Subject who had taken medicine(Barbital etc) related drug metabolizing enzyme
             induction or inhibition within 1 month prior to the drug administration

          -  Subject who had taken prescription drug or oriental medicine within 2 weeks or OTC
             drug or vitamin formulation within a week prior to the drug administration

          -  Subject who had a diet which can affect the absorption, distribution, metabolism or
             elimination of Rosuvastatin/Metformin (Particulary, Grapefruit - within 48h prior to
             the drug administration)

          -  Subject who donated whole blood within 2 month or component blood within 1 month
             prior to the drug administration

          -  Subject who smokes more than 10 cigarettes per day

          -  Subject who has positive HBsAg, HCV Ab or HIV Ab

          -  Subject who is judged to be ineligible by principal investigator or sub-investigator
             according to various test results(clinical laboratory test, 12-lead ECG etc)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jangsoo Yoon, M.D.</last_name>
      <phone>82-2-2072-1666</phone>
      <email>arpe00@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Kyung-Sang Yu, M.D. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 22, 2013</lastchanged_date>
  <firstreceived_date>November 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Rosuvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
